WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended December 31, 2025 and provide an update on recent developments in its business after market close on Wednesday, March 4, 2026. Management will host a conference call ...

Core Viewpoint - Aquestive Therapeutics, Inc. is actively participating in the Piper Sandler 37th Annual Healthcare Conference, highlighting its commitment to advancing innovative medicines and engaging with investors [1][2]. Company Overview - Aquestive Therapeutics is a pharmaceutical company focused on improving patients' lives through innovative science and delivery technologies, developing orally administered and topical gel products to deliver complex molecules [4]. - The company has four commercialized products marketed by licensees in the U.S. and globally, and it is the exclusive manufacturer of these licensed products [4]. - Aquestive is advancing a late-stage proprietary product candidate for treating severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel for dermatology conditions [4]. Upcoming Events - The management team will hold a fireside chat on December 4, 2025, focusing on the product candidate Anaphylm™ (dibutepinephrine) sublingual film, discussing regulatory progress and commercial readiness [2]. - Investor meetings will also be hosted on the same day, providing opportunities for direct engagement with the management team [2]. Communication and Accessibility - A webcast of the fireside chat will be available on the company's website, with a replay accessible for 30 days post-event [3].

Core Insights - A significant rally occurred in the biotech and healthcare sectors on October 9, with multiple stocks reaching 52-week highs, driven by regulatory milestones, strategic announcements, and investor enthusiasm around clinical progress [1] Company Highlights - Aquestive Therapeutics Inc. (AQST) achieved a 52-week high of $6.86, closing at $6.69, following the announcement of a new U.S. patent for its PharmFilm, enhancing its position in oral drug delivery platforms [2] - Ascendis Pharma A/S (ASND) reached a 52-week high of $216.45, closing at $214.77, coinciding with the submission of a Marketing Authorisation Application to the European Medicines Agency for its investigational therapy targeting achondroplasia in children [3] - Cidara Therapeutics Inc. (CDTX) advanced 12.44% to close at $110.76, hitting a 52-week high of $111.35 after receiving Breakthrough Therapy designation from the FDA for its antiviral candidate CD388 [4] - Intellia Therapeutics Inc. (NTLA) surged 4.05% to end at $25.46, with a new 52-week high of $26.99, driven by optimism surrounding its in vivo CRISPR programs and recent trial updates [5] - Organigram Global Inc. (OGI) gained 4.12% to close at $2.02, reaching a 52-week high of $2.08, following the launch of its new hemp-derived delta-9 brand "happly" targeting mindful recreation consumers [6] - uniQure N.V. (QURE) rose 6.14% to finish at $63.65, with a 52-week high of $65.12, supported by analyst upgrades and renewed interest in its gene therapy candidate for Huntington's disease [7] - REGENXBIO Inc. (RGNX) closed slightly lower at $12.17 but reached a 52-week high of $12.84, presenting interim Phase II data for ABBV-RGX-314 at a major ophthalmology meeting [8] - Tempus AI Inc. (TEM) saw a decline of 3.85% to $99.28 after hitting a 52-week high of $104.32, despite being selected by ARPA-H for a federal precision cancer therapy initiative [9] - Tilray Brands, Inc. (TLRY) jumped 22.09% to close at $2.10, reaching a 52-week high of $2.32, reporting a return to profitability with record quarterly revenue of $210 million [9] - Zenas BioPharma (ZBIO) gained 7.18% to end at $27.76, hitting a 52-week high of $28.72 after announcing a licensing agreement and a $120 million private placement to support its autoimmune pipeline [10] - Brookdale Senior Living Inc. (BKD) rose 9.36% to close at $8.88, reaching a 52-week high of $9.09, reporting its highest occupancy rate in over a year at 82.5% [11]

Core Viewpoint - Aquestive Therapeutics, Inc. is actively engaging with investors through participation in three upcoming conferences in September 2025, showcasing its commitment to transparency and investor relations [1]. Company Overview - Aquestive Therapeutics is a pharmaceutical company focused on advancing medicines that significantly improve patients' lives through innovative science and delivery technologies [2]. - The company is developing orally administered products to deliver complex molecules, providing alternatives to invasive and inconvenient standard therapies [2]. - Currently, Aquestive has four commercialized products marketed by its licensees globally and is the exclusive manufacturer of these products [2]. - The company collaborates with other pharmaceutical firms to bring new molecules to market using proprietary technologies, such as PharmFilm [2]. - A late-stage proprietary product candidate for treating severe allergic reactions, including anaphylaxis, is under development, along with an early-stage epinephrine prodrug topical gel for dermatological conditions like alopecia areata [2]. Upcoming Events - The company will participate in the Cantor Healthcare Conference with a fireside chat scheduled for 8:00 am ET on September 4, 2025, and will host investor meetings on September 3 and 4 [4]. - At the Wells Fargo Healthcare Conference, the company will be available for investor meetings on September 5 [4]. - The H.C. Wainwright 26th Annual Global Investor Conference will feature a presentation at 10:00 am ET on September 9, 2025, with investor meetings available on September 8 and 9 [4].

Company Overview - Aquestive Therapeutics, Inc. is a pharmaceutical company focused on advancing medicines to improve patients' lives through innovative science and delivery technologies [2] - The company develops orally administered and topical gel products to deliver complex molecules, providing alternatives to invasive standard therapies [2] - Currently, Aquestive has four commercialized products marketed by its licensees in the U.S. and globally, and it is the exclusive manufacturer of these products [2] Product Development - The company is advancing a late-stage proprietary product candidate for treating severe allergic reactions, including anaphylaxis [2] - An early-stage epinephrine prodrug topical gel product candidate is also in development for various dermatological conditions, including alopecia areata [2] Upcoming Events - The management team of Aquestive will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 9, 2025, which will include panels on key therapeutic themes in immunology, inflammation, and metabolism [1]